Largest real-world analysis of AI-driven breast cancer screening in U.S. history1 demonstrates increased cancer detection rate with consistent benefits across patient populations LOS ANGELES and SOMERVILLE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), the nation's largest provider of outpatient diagnostic imaging services, and its wholly owned subsidiary, DeepHealth, a global leader in AI-powered health informatics, today announced results... Read more
Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million
Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million
Updated Time of Company Presentation at Jefferies Global Healthcare Conference WEST LAFAYETTE, Ind., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development... Read more
WILMINGTON, Mass. / Nov 17, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18th, at 11:30 a.m. GMT (6:30 a.m. ET). Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends.
A live webcast of the presentation will be available through a link that will be posted on the... Read more
ANN ARBOR, Mich. / Nov 17, 2025 / Business Wire / ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today provided a business update and reported financial results for the three and nine months ended September 30, 2025.
Business Updat... Read more
Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter NEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for the remainder of 2025.
Q3-2025 Financial Results: Revenues. Q3-2025 revenues reached $6.8M, a 30% increase YoY from $5.2M in Q3-2024,... Read more
DUBLIN, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with a leading bioinformatics company to conduct advanced analysis on clinical trial data for EpiCapture, the company’s PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to... Read more
Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset CHICAGO / Nov 14, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, nonprofit, private foundation dedicated to accelerating the... Read more
Company achieves 86% increase in CyPath® Lung testing revenue, strengthens balance sheet SAN ANTONIO / Nov 14, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended September 30, 2025.
Key Highlights CyPath® Lung revenues increased 86% year over year for... Read more
SOUTH SAN FRANCISCO, Calif. / Nov 14, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2025 ended September 30, 2025.
Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2025 earnings... Read more
Second study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor outcomes FRIENDSWOOD, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the clinical value of its DecisionDx-Melanoma test... Read more
MENLO PARK, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: Wolfe Research Healthcare Conference 2025 in New York, NY Fireside chat on Tuesday, November 18 at 8:40 AM ET Jefferies Global Healthcare Conference in London, UK Hosting 1x1 meetings only on Wednesday, November... Read more
LINCOLN, Neb. / Nov 13, 2025 / Business Wire / NRC Health, the leader in healthcare experience management, is proud to announce a new partnership with BJC Health System, one of the nation’s largest nonprofit integrated healthcare delivery organizations. The collaboration will unify and elevate patient and employee experiences across BJC’s hospitals, clinics, and academic partners, reinforcing its mission to improve the health and well-being of the people and communities... Read more
Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ("Telo" or the "Company"), a leader in diagnostic and prognostic innovation through its proprietary multi-factor telomere analytics, today announced that it will deliver an industry presentation at the 2025 Myeloma Canada MRD Testing Implementation Summit, taking place November 14–15.
Dr. Yulia Shifrin, Laboratory Director at Telo Genomics, will highlight the Company's... Read more
Company Reports $13.8M in Q3 Revenue as Refocusing and Cost Cutting Initiatives Drive Improved Late Quarter Performance with Accelerated Sequential Improvements Expected in Q4 and into 2026 HALLANDALE BEACH, Fla., Nov. 13, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today... Read more
SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025.
Third Quarter and Recent Highlights: Meaningful progress on payer initiatives, including an inaugural pilot in Nevada actively enrolling... Read more
Third quarter 2025 revenue was $5.0 million, compared to $7.4 million in the third quarter of 2024, and $5.4 million in the second quarter of 2025
Targeting $12.4 million in new business, reflecting both committed annual recurring revenue ("CARR") and late-stage opportunities nearing completion; 2026 pipeline expanded to $69 million
Exceeded 2025 goal of 40 new signed accounts for 2026 revenue, with 45 new signed accounts to date—several already contributing to 2025... Read more
Conference call to discuss financial and operational results scheduled for Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nevada, Nov. 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter ended September 30, 2025. Volition management will host a conference call tomorrow, November 14 at 8:30 a.m. U.S. Eastern... Read more
Commercial Readiness Plans Accelerating in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software for Arrhythmia Assessment
Anticipated FDA Clearance in Q4 2025 is a Major Inflection Point as HeartBeam Evolves into a Commercial-Stage Company Focused on Growth
Announced Partnership with HeartNexus to Provide On-Demand Cardiologist Reviews of Synthesized 12-Lead ECGs for Arrhythmia Assessment and Triage Patients
Data... Read more
SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Business Highlights: Performed in-silico analysis of the primer sets used in its Co-Primers®-based PCR tests for the detection... Read more
Conference call today, November 13, 2025, at 4:30 PM ET SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2025.
“Over the last year, we have taken decisive steps to transform our business model by focusing on driving consumables and software utilization among our existing routine use customers. We believe our performance in the third quarter and year-to-date... Read more
Collaboration aims to expand existing U.S. relationship combining GE HealthCare’s mammography systems with DeepHealth’s Breast Suite to include a worldwide distribution arrangement
Intends to integrate GE HealthCare’s ultrasound imaging with DeepHealth’s AI-powered Thyroid Suite for intelligent clinical decision support and advanced automation
Creates a proposed offering combining DeepHealth’s remote scanning solution, TechLive™, with GE HealthCare’s... Read more
Q3 revenues increased by 18% to $27.4 million
Adjusted EBITDA profitability of $1.0 million for Q3
Acquisition of ExoDx business from Bio-Techne Corporation
Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA – November 12, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the three and nine-month period... Read more
Initiates Full Year 2025 Revenue Guidance of $173.0 Million to $173.5 Million MOUNTAIN VIEW, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today reported financial results for the three months ended September 30, 2025.
Third Quarter 2025 Highlights Total revenue of $46.3 million, a 41% increase year-over-year
Gross margin of 76.5%, non-GAAP... Read more
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood pressure and cholesterol
Results demonstrate the advantages of WGS over WES and genotyping arrays for assessing genetic risk and identifying drug target candidates. SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- A study published today in Nature, authored by Illumina, Inc.... Read more
New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, announced that TriWest, the regional administrator for TRICARE, has updated... Read more
Analysis based on claims data highlights significant cost savings, especially among high-risk members NEW YORK, Nov. 12, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the presentation of research on new real-world evidence of medical cost reduction at ISPOR Europe 2025, one of the world's premier health economics and outcomes research conferences, currently taking... Read more
34-member consortium creates an interoperable data standard for AI and distributed analytics
Notable founding members include Guardant Health, NetApp, Seagate, IBM, DDN, and Genentech PALO ALTO, Calif. / Nov 12, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the public launch of the Single Namespace Working Group (SNS), a 34-member, cross-industry consortium which has drafted the first open standard for... Read more
First-of-its-kind, automated system delivers increased sensitivity, specific identification of disease markers and improved laboratory workflow to support fast, confident diagnoses WALTHAM, Mass. / Nov 12, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced 510(k) clearance of the EXENT® Analyser and Immunoglobulin Isotypes (GAM) Assay**, a first-of-its-kind automated platform for clinical laboratories.... Read more
BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of the world’s leading healthcare trade shows, taking place from 17–20 November, 2025, in Düsseldorf, Germany.
With over 5,000 exhibitors from 70 countries and 80,000 visitors... Read more
Streamlined electronic access now available for Natera’s clinical oncology portfolio across Flatiron Health’s network of 4,500+ cancer care providers AUSTIN, Texas / Nov 12, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Natera’s oncology... Read more
DUBLIN / Nov 12, 2025 / Business Wire / ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation, today announced that Mr. Barry Balfe, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc, will present at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 am GMT.
Any changes to this event and links to the live webcast (where available) will be posted on the Investor section of our website under “Events”.
About ICON plc
ICON... Read more
WASHINGTON, Nov. 11, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Jefferies Global Healthcare Conference in London, UK on Tuesday, November 18, 2025 at 11:00 a.m. GMT. The event will be simultaneously webcast on www.danaher.com.
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology... Read more
SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Wolfe Research Healthcare Conference 2025 on November 19, 2025Fireside chat at 6:20am Pacific Time (9:20am Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on Illumina's website after the event and... Read more
Drives efficiency and reliability in Quality Control and Development environments, integrating seamlessly with world-class Empower™ Chromatography Data System (CDS).
Mitigates CDS communication errors encountered in up to 70% of multi-vendor LC-CAD configurations.1
Delivers near-universal detection of an expansive range of analytes across pharmaceutical formulations, food additives, and environmental pollutants, including those that are challenging to measure... Read more
FRIENDSWOOD, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2, 2025, at 1:10 p.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’... Read more
Acquisition supplements CIMAR’s cloud-native infrastructure with DeepHealth’s AI-powered informatics to deliver connected, efficient and accessible care LOS ANGELES and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a US leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today the acquisition of CIMAR UK, a leading provider of cloud-native healthcare image management... Read more
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed
Sydney Mass Spectrometry is the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, adding to a growing list of institutions revealing biological insights with exceptional clarity at scale
Recent collaborations and projects including Genomics... Read more
100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk® Hereditary Cancer Test—the gold standard in germline testing—has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1 and guidelines... Read more
New Guardant Reveal offering provides oncologists with tissue-free solution to monitor treatment response and detect early disease progression with unprecedented speed and sensitivity
Reveal is clinically validated in confirming effective therapies earlier and optimizing treatment faster in patients with advanced cancer PALO ALTO, Calif. / Nov 10, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion... Read more
Acquisition deepens Revvity Signals’ presence in research informatics while furthering its ongoing expansion into development and manufacturing solutions WALTHAM, Mass. / Nov 10, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end... Read more
Total Revenue Surges 568% YoY to $23.6 million;
IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M);
IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026
IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics
Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025... Read more
MADISON, Wis. / Nov 10, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) for its previously announced license agreement with Freenome. Under the agreement, the Company acquired exclusive rights in the United States to Freenome’s blood-based colorectal cancer (CRC) screening tests.... Read more
QIAsymphony Connect, the next generation of automated nucleic acid purification platform, to be shown at AMP 2025 as early access phase begins ahead of full release in mid-2026
QIAGEN showcases Sample to Insight workflows for comprehensive genomic profiling (CGP) based on Element Biosciences Trinity™ technology
Partnership with Myriad Genetics Inc. to highlight development of a homologous recombination deficiency (HRD) assay for use in cancer profiling GERMANTOWN,... Read more
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce its financial results for the three months and nine months ended September 30, 2025.
Financial and Operational Highlights Revenues were $4.84 million in the third quarter compared to $4.45 million in the same period the prior year, an increase of 8.7%. For the nine months ended September 30, 2025, revenues... Read more
Total Company Revenue increased 13.4% to $522.9 million in the third quarter of 2025 from $461.1 million in the third quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 51.6% to $24.8 million in the third quarter of 2025 from $16.4 million in the third quarter of 2024
Total Company Adjusted EBITDA(1) was $84.9 million in the third quarter of 2025 as compared with $73.7 million in the third quarter of 2024,... Read more
Multicenter outcomes FISH&CHIPS study of nearly 8,000 patients confirms total plaque volume as a powerful independent predictor of long-term cardiovascular events NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Association (AHA) Scientific Sessions 2025. The new... Read more
Oncoguard® Liver blood test delivers seven times greater sensitivity for very early-stage hepatocellular carcinoma (HCC) versus standard of care
ALTUS study is the largest prospective trial of a blood test for liver cancer surveillance in the United States, reflecting the racial and ethnic diversity of high-risk groups MADISON, Wis. / Nov 07, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today... Read more
PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactions
Company to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the third quarter and provided a corporate update.
The... Read more
Revenue of $84.1 million, growing 17% year-over-year
Raising Full Year 2025 Revenue Guidance to $325.0 million
Raising Full Year 2025 EPS Guidance to GAAP loss of approximately ($1.70) per share and Non-GAAP income of $0.30 per share
GAAP gross profit of $35.5 million, or GAAP gross margin of 42.2%; Non-GAAP gross profit of $37.2 million, or Non-GAAP gross margin of 44.3%
GAAP loss of $6.6 million, or ($0.21) per share; Non-GAAP income of $4.5 million, or $0.14 per... Read more
AUSTIN, Texas / Nov 06, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025.
Recent Financial Highlights Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34.7%. Product revenues grew 35.3% over the same period.
Generated a gross margin... Read more
